Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575323 | 0.78 | TSHR (0.42) | TP53TDP1TSHRPPARDACHE | |
| SCHEMBL5500698 | 0.77 | TSHR (0.55) | TP53TDP1TSHRPPARDACHE | |
| SCHEMBL18309148 | 0.73 | — | — | |
| SCHEMBL575282 | 0.73 | — | — | |
| SCHEMBL18650115 | 0.70 | TP53 (0.41) | TP53TDP1TSHRPPARDHMGCR | |
| SCHEMBL24052953 | 0.69 | — | — | |
| SCHEMBL16785847 | 0.69 | TSHR (0.48) | TP53TDP1TSHRPPARDACHE | |
| SCHEMBL7013841 | 0.69 | — | — | |
| SCHEMBL8764678 | 0.69 | — | — | |
| SCHEMBL575221 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034851-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140235583-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235583-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | TP53 692/4885TDP1 1525/4885TSHR 2794/4885 |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | TP53 4472/4885TDP1 3324/4885TSHR 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.